Log In
Print
BCIQ
Print
Print this Print this
 

Lestaurtinib (CEP-701) (formerly KT-5555)

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionInhibitor of several tyrosine kinases including FMS-like tyrosine kinase 3 (FLT3) and janus kinase-2 (JAK-2)
Molecular Target FMS-like tyrosine kinase 3 (FLT3) (CD135)
Mechanism of ActionFMS-like tyrosine kinase 3 (FLT3) inhibitor
Latest Stage of DevelopmentPhase I/II
IndicationMyeloproliferative disorder
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today